Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multi-Dose Study of SGN-40 (Anti-huCD40 mAb) in Patients With Chronic Lymphocytic Leukemia

NCT00283101 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT00283101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00283101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multi-Dose Study of SGN-40 (Anti-huCD40 mAb) in Patients With Chronic Lymphocytic Leukemia
Lead sponsor
Seagen Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2005
Completion date
October 31, 2006
Enrollment
12 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphocytic, chronic